xenon-129
Trade name: Xenoview
Approved
Dec 23, 2022
Naturally occurring xenon (54Xe) consists of seven stable isotopes and two very long-lived isotopes. Double electron capture has been observed in 124Xe and double beta decay in 136Xe, which are among the longest measured half-lives of all nuclides. The isotopes 126Xe and 134Xe are also predicted to undergo double beta decay, but this process has never been observed in these isotopes, so they are considered to be stable. Beyond these stable forms, 32 artificial unstable isotopes and various isomers have been studied, the longest-lived of which is 127Xe with a half-life of 36.342 days. All other nuclides have half-lives less than 12 days, most less than 20 hours. The shortest-lived isotope, 108Xe, has a half-life of 58 μs, and is the heaviest known nuclide with equal numbers of protons and neutrons. Of known isomers, the longest-lived is 131mXe with a half-life of 11.948 days. — Wikipedia
Clinical trial activity
65 trials · 44 clinical orgs · 1 marketing orgs
Earliest trial started Sep 30, 1997 (NCT03764163)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2018
Polarean Inc. — Earliest Phase 3 Sponsor(trial)
2020s
- Dec 23, 2022
Polarean Inc. — Earliest FDA Approval
- Dec 23, 2022
Polarean Inc. — Marketing Organization
- Dec 23, 2022
Polarean Inc. — NDA Secondary Org
- Dec 23, 2022
Polarean Inc. — NDA Organization
Indications
Approved for
Studied for
- Allergy and Immunology · Early Phase 1
- Alveolitis, Extrinsic Allergic · Phase 2
- Alzheimer Disease · Early Phase 1
- Anemia · Phase 2
- Anesthesia · Early Phase 1
- Anxiety · Early Phase 1
- Asbestosis · Early Phase 1
- Asthma · Phase 2
- Bipolar Disorder · Early Phase 1
- Brain Ischemia · Phase 2
- Bronchiectasis · Early Phase 1
- Bronchiolitis Obliterans · Phase 1/Phase 2
- Bronchopulmonary Dysplasia · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Cerebral Arteries · Phase 2
- Cerebral Infarction · Phase 2
- Common Cold · Early Phase 1
- Connective Tissue Diseases · Phase 2
- COVID-19 · Phase 2
- Cystic Fibrosis · Phase 4
- Dyspnea · Phase 2
- Electronic Nicotine Delivery Systems · Phase 2/Phase 3
- Emphysema · Early Phase 1
- Familial Primary Pulmonary Hypertension · Phase 2
- Fibrosis · Phase 2
- Healthy Volunteers · Phase 1
- Heart Diseases · Phase 2
- Heart Failure · Phase 2
- Hypertension · Phase 2
- Hypertension, Pulmonary · Phase 2
- Idiopathic Pulmonary Fibrosis · Phase 2
- Infections · Phase 1
- Ischemic Stroke · Phase 3
- Liver · Phase 4
- Lung · Early Phase 1
- Lung Diseases · Phase 4
- Lung Diseases, Interstitial · Phase 2
- Lung Neoplasms · Early Phase 1
- Lung Transplantation · Phase 2
- Major Depressive Disorder · Early Phase 1
- Mesothelioma · Early Phase 1
- Obesity · Phase 2
- Panic Disorder · Phase 2/Phase 3
- Parkinson Disease · Phase 1
- Polycythemia · Phase 2
- Pulmonary Arterial Hypertension · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 2/Phase 3
- Pulmonary Embolism · Phase 2
- Pulmonary Fibrosis · Early Phase 1
- Pulmonary Surgical Procedures · Phase 3
- Radiation Injuries · Phase 1
- Respiratory Tract Infections · Early Phase 1
- Sleep Apnea, Obstructive · Phase 4
- Stress Disorders, Post-Traumatic · Phase 2/Phase 3
- Stress, Psychological · Early Phase 1
- Subarachnoid Hemorrhage · Phase 2
- Vaping · Phase 1/Phase 2
- Xenon · Early Phase 1
Mechanism of action
- UnclearUnclear
Unclear unclear
Approval history
- approvedDec 23, 2022
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIsotopes of xenon ↗
Also known as
- 129-xenon
- ge-141, hyperpolarized 129xenon gas
- hyperpolarized xenon
- xenon-129
- xenon-129
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06909201 | Early Phase 1 (Phase 1) | Oct 16, 2025 | University of Texas at Houston |
| NCT06925295 | Phase 2 | Aug 31, 2025 | University of Iowa |
| NCT06945614 | Phase 1 | Apr 16, 2025 | General Biophysics LLC, National Institute on Aging (NIA) |
| NCT06853145 | Early Phase 1 (Phase 1) | Mar 31, 2025 | University of Virginia |
| NCT06856525 | Phase 2/Phase 3 (Phase 3) | Dec 6, 2024 | Duke University, George Mason University, University of Virginia |
| NCT06351345 | Phase 2 | Sep 1, 2024 | Duke University, Merck |
| NCT06122922 | Phase 2 | Mar 15, 2024 | Duke University, Regeneron |
| NCT06038630 | Phase 2 | Jan 31, 2024 | Duke University, National Institutes of Health (NIH) |
| NCT06104228 | Phase 2 | Jan 1, 2024 | American Heart Association, Duke University |
| NCT06080100 | Early Phase 1 (Phase 1) | Nov 1, 2023 | GMP BIO Co., LTD., The S.N. Fyodorov Eye Microsurgery State Institution |
| NCT05838703 | Phase 2 | May 1, 2023 | Duke University |
| NCT05550662 | Phase 2 | Jan 15, 2023 | University of Toronto |
| NCT05335109 | Phase 3 | Dec 1, 2022 | Negovsky Reanimatology Research Institute |
| NCT05433961 | Phase 1 | Aug 1, 2022 | University of Pennsylvania, Xemed LLC |
| NCT05241275 | Phase 2 | Jul 19, 2022 | Boehringer Ingelheim, Duke University |
| NCT05517655 | Phase 4 | May 1, 2022 | University of Cincinnati, University of Iowa, University of Kansas, University of Virginia |
| NCT05302817 | Phase 1 | Mar 17, 2022 | University of Pennsylvania, Xemed LLC |
| NCT04677426 | Phase 2 | Jan 1, 2022 | Boehringer Ingelheim, Duke University, University of Cincinnati, University of Kansas |
| NCT04778046 | Phase 2 | Dec 1, 2021 | Duke University |
| NCT04855305 | Phase 2 | Nov 12, 2021 | Duke University, National Heart, Lung, and Blood Institute (NHLBI), University of Cincinnati, University of Iowa |
Organizations
Research & Development (44)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 20 | 17 | 3 | 2015 |
| University of Cincinnati | Academic/Hospital | 9 | 7 | 2 | 2014 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 7 | 0 | 2 | 1997 |
| University of Virginia | Academic/Hospital | 7 | 6 | 4 | 2016 |
| University of Western Ontario | Academic/Hospital | 6 | 3 | 2 | 2011 |
| National Institutes of Health (NIH) | Government | 5 | 0 | 3 | 1997 |
| University of Iowa | Academic/Hospital | 4 | 2 | 3 | 1997 |
| University of Kansas | Academic/Hospital | 4 | 3 | 3 | 2020 |
| University of Pennsylvania | Academic/Hospital | 4 | 0 | 1 | 2019 |
| Xemed LLC | For profit | 4 | 4 | 1 | 2019 |
| Nobilis Therapeutics Inc. | For profit | 3 | 3 | 2 | 2018 |
| Boehringer Ingelheim | For profit | 2 | 0 | 1 | 2022 |
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2013 |
| Lakehead University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Northern Ontario School of Medicine | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Polarean Inc. | For profit | 2 | 2 | 1 | 2018 |
| University of Toronto | Academic/Hospital | 2 | 2 | 1 | 2015 |
| American Heart Association | Academic/Hospital | 1 | 0 | 1 | 2024 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2019 |
| Cystic Fibrosis Foundation Therapeutics | Academic/Hospital | 1 | 0 | 1 | 2018 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Polarean Inc. | For profit | MKTG | Dec 23, 2022 |
| Polarean Inc. | For profit | NDA2 | Dec 23, 2022 |
| Polarean Inc. | For profit | NDA | Dec 23, 2022 |